Phase III trial of Rapamune versus placebo in primary renal allograft recipients

By Ponticelli C.   MacDonald A.S.   Rajagopalan P.   Sindhi R.   Mathew T.   for the Rapamicin Global Study Group  

Transplantation Proceedings, Vol. 33, Iss. 3, 2001-05 ,pp. : 2271-2272

Elsevier

Access to resources Recommend Favorite

Individualization of maintenance immunosuppressive therapy equalizes acute rejection risk in African American versus non-African American renal allograft recipients

By Lewis R.   Coutee J.   Kostro B.   Calvert D.   Cava-Bartsch C.   Susskind B.   Swies G.   Burns T.  

Transplantation Proceedings, Vol. 33, Iss. 6, 2001-09 ,pp. : 2977-2979

Elsevier

Access to resources Recommend Favorite

Late Acute Rejection is More Prevalent Among African-American Renal Allograft Recipients and is Frequently Associated With Allograft Loss

By Vasquez E.M.   Benedetti E.   Pollak R.  

Transplantation Proceedings, Vol. 30, Iss. 4, 1998-06 ,pp. : 1173-1175

Elsevier

Access to resources Recommend Favorite

Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients

By Park K.   Kim S.I.   Moon J.I.   Kim Y.S.   Kim M.S.  

Transplantation Proceedings, Vol. 30, Iss. 7, 1998-11 ,pp. : 3575-3575

Elsevier

Access to resources Recommend Favorite

Risk of Acute Cellular Rejection After Azathioprine Withdrawal in Stable Renal Allograft Recipients on Cyclosporine, Azathioprine, and Prednisone

By Fabrega A.J.   Roy G.   Reynolds L.   Corwin C.   Hunsicker L.  

Transplantation Proceedings, Vol. 30, Iss. 4, 1998-06 ,pp. : 1335-1336

Elsevier

Access to resources Recommend Favorite